Absolutely, high possibility of Cantrixil deal before Kazia's AGM, especially after management's comments in the 2020 Annual Report.
Looking forward to confirmation of the first patient recruitment in the GBM AGILE study for Paxalisib. and the next 200 patients over the following 12 months.
Looking forward to the first interim data next year from the ALLIANCE study for Paxalisib.
Regards.
- Forums
- ASX - By Stock
- KZA
- Effects of PI3K Inhibition on Peripheral Leukocytes in Metastatic Breast Cancer
Effects of PI3K Inhibition on Peripheral Leukocytes in Metastatic Breast Cancer, page-11
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)